Aptevo Therapeutics Inc. (APVO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 5M 10M 15M FY21: 12.3M FY22: 3.1M FY21 FY22

Gross Profit Annual

0 5M 10M 15M FY18: 11.9M FY19: 12.5M FY18 FY19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-27M -18M -9M 0 9M 18M 27M FY24: -24.6M FY25: -26.3M FY24 FY25

Net Income Annual

-27M -18M -9M 0 9M 18M 27M FY24: -24.1M FY25: -26M FY24 FY25

Cost of Revenue Annual

0 7M 14M 21M FY18: 11.2M FY19: 19.9M FY18 FY19

Operating Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY24: -23.8M FY25: -25.6M FY24 FY25

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY21: -22.4M FY22: -21.1M FY21 FY22

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 150K 300K 450K FY24: 767 FY25: 315.5K FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45000.00 -30000.00 -15000.00 0.00 15000.00 30000.00 45000.00 Q4 '23: -2319.34 Q1 '24: -2704.93 Q2 '24: -3887.94 Q3 '24: -4223.64 Q4 '24: -29713.50 Q1 '25: -30927.10 Q2 '25: -29841.43 Q3 '25: -29485.80 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.